

**Curriculum Vitae**  
Oliver Eric Michael Lily

*March 2017*

## Personal details

**Name:** Oliver Eric Michael Lily

**Address:** 94 Pannal Ash Road  
Harrogate  
HG2 9AJ

**Telephone:** (01423) 874232

**Email:** Oliver.lily@nhs.net

**Nationality:** British

**Date of Birth:** 20 April 1971

**Age:** 45

**Marital Status:** Married with 4 daughters.

**Qualifications:** BSc(*hons*) MB ChB(*hons*) MD FRCP

**Registration:** No. 4204389

## **General Education**

*1982-1989*

Simon Langton Grammar School, Canterbury

‘O’ Levels: 10 Grade A

‘A’ Levels: Chemistry, Physics and Biology (Grade A)

‘S’ Levels: Chemistry (Distinction)  
Physics (Merit)

## **Medical Education**

*1989-1995*

School of Medicine, University of Leeds

MB ChB (with Honours)

1993 Intercalated BSc Pharmacology (First Class Honours)

Included original research project and presentation on the mechanism of the vasodilator action of adenosine. (Supervisor - Dr MS Yates)

*1997*

MRCP Part I (London)

*1998*

MRCP Part II (London)

*2003*

MD (University of Leeds)

*2009*

FRCP (London)

## **Prizes and Distinctions**

*1993*

Leeds Health Authority Scholarship for intercalated year

*1994*

Distinction in Obstetrics and Gynaecology

*1995*

William McAdam Prize in Medicine (Leeds University)

*1995*

Yorkshire Urological Audit Group

Runner-up prize for best paper presentation

*2000*

Vandrell-Evans award for Neuroscience research (Leeds University)

*2001*

Liversedge Prize for best presentation (NENA)

*2005*

Magnum for best case presentation (NENA)

## Present Post

*Aug 2005-*

### **Consultant Neurologist**

**The General Infirmary at Leeds and Harrogate District Hospital**

With special responsibility for the multiple sclerosis treatment service and including emergency on-call work and general neurology clinics. I am also Lead Clinician for Neurology and Honorary Senior Lecturer in Neurology for the University of Leeds.

## Previous Posts

*May 2005-July 2005*

### **Acting Consultant Neurologist**

**St James University Hospital, Leeds**

*Aug 2001 -July 2005*

### **Specialist Registrar in Neurology – Yorkshire Deanery**

*Aug 2001-Oct 2001*

**St James University Hospital, Leeds**

*May 2004-April 2005*

*Nov 2001-April 2003*

**Pinderfields General Hospital, Wakefield**

*May 2003-April 2004*

**The General Infirmary at Leeds**

## Research

### **Principle Investigator: Leeds general Infirmary 2005-present:**

MSSMART (Co-investigator)

Lemtrada-PASS (Sanofi)

Sanofi-Aventis TERI-PRO phase 4 trial of teriflunamide

Sanofi-Aventis EFC6058 TERACLES study of teriflunamide and interferon

Sanofi-Aventis EFC10531 TOWER study of teriflunamide in MS

Weleda 25-01 MUSEC trial of cannabis extract

Teva TPL/2006/4001 SWITCH follow-up study

Bayer BEGIN Exercise data gathering in early MS

Walton Clinical Trials Unit; Sequential mitoxantrone and Glatirimer acetate or interferon 1a in early severe MS

### **Treating physician: Oxford Radcliffe Infirmary, 1999-2001**

Ares-Serono 6954 "PRISMS" trial of beta-interferon in secondary progressive MS

Bayer 10-5230/0103 trial of intravenous immunoglobulin in secondary progressive MS

Teva "CORAL" trial of oral copolymer 1 in relapsing-remitting MS.

### **Evaluating neurologist: Oxford Radcliffe Infirmary, 1999-2001**

Elan AN100226 231 trial of intravenous "Antegren" (recombinant humanised anti-alpha4 integrin antibody).

*Aug 1999–Jul 2001*     **Research Fellow in Clinical Neurology**  
University of Oxford  
Neurosciences Group  
Institute of Molecular Medicine

Supervised by Dr Jackie Palace, Consultant Neurologist, Radcliffe Infirmary and Professor Angela Vincent, Professor of Neuroimmunology, Oxford University

In spite of the classification of multiple sclerosis (MS) as an autoimmune disorder, it has so far not proved possible to convincingly demonstrate specific autoantibodies from MS patients that bind to any of the proposed oligodendrocyte or myelin antigens. Using a number of new techniques in immunohistochemistry and flow cytometry, I have undertaken a systematic search for specific autoantibodies in MS patients and tried to assess their relevance using detailed clinical information. I have been particularly interested in autoantibodies against neuronal antigens, antigens expressed by oligodendrocyte precursor cells and inducible antigens such as heat-shock proteins. The results have been published in full. (*Brain* 2004; 127:269-79)

This work resulted in the award of MD by Leeds University

## **Other activities:**

### **Research and audit**

- I have collaborated closely with other researchers in the field of multiple sclerosis including a group investigating CD8 T-cell responses (Dr David Price - *J Biol Chem.* 2002 Jun 7;277(23):20840-6) and the development of a new immunoprecipitation assay for anti-interferon antibodies (Natasha Lawrence - *J Neurol Neurosurg Psychiatry.* 2003 Sep;74(9):1236-9.).
- I have helped establish a bank of frozen serum and whole blood samples from multiple sclerosis patients and those with other neurological diseases, indexed with clinical details for future research.
- I have been invited to review research publications on multiple sclerosis for several journals including *The Lancet*.
- I attend regularly international neurology meetings including the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS), the British Society for Immunology Congress, the world Congress for Neurology, the European Neurological Society and the Association of British Neurologists.

## General medical Training

Feb 1999      **Senior House Officer - Neurology**  
- Aug 1999      St. James University Hospital, Leeds

August 1996   **Senior House Officer - Medical Rotation**  
- Feb 1999      The General Infirmary at Leeds

## Professional Associations

1993                      British Medical Association  
1993                      Medical Protection Society  
1998                      Royal College of Physicians  
1999                      Association of British Neurologists (Associate Member)  
2001                      North of England Neurological Association

## Publications

Shanmugarajah PD, Alty J, Lily O, Ford HL. Lesson of the month 2: Transient reversible amnesia in multiple sclerosis. Clin Med (Lond). 2017 Feb;17(1):88-90.

Confavreux C *et al.* Oral teriflunamide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology 2014 13(3):247-56

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012 Nov;83(11):1125-32.

Maniyar F, Rooney C, Lily O, Bazaz R. Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis. J Neurol. 2009 Mar 30.

Lily O, McFadden E, Hensor E, Johnson M, Ford H. Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler. 2006 Dec;12(6):808-13.

Hassan A, Lily O, Johnson M, Henderson B, Twomey A, Hassan S, Al-Din A. Adult onset SSPE: Experiences in West Yorkshire over a 12 month period. J Neurol Neurosurg Psychiatry 2005; 76(9): 1310-11

Al-Din A S, Mir R, Davey R, Lily O, Ghaus N. Trigeminal cephalgias and facial pain syndromes associated with autonomic dysfunction. Cephalgia 2005; 25(8): 605-11

Lily O, Al-Din AS. Case study: cerebrovascular Parkinsonism with levodopa addiction. J Neurol Neurosurg Psychiatry 2004; 75(9):1365-6

Lily O. Chronic autoimmune disease caused by somatic mutation to T-lymphocyte regulatory receptors. Med Hypotheses. 2004;62(4):582-6.

Lily O, Palace J, Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain. 2004;127(Pt 2):269-79.

Lily O. Epstein-Barr virus and risk of multiple sclerosis. JAMA. 2003;290(2):192 (letter)

Lily O, Vincent A, Palace J. Serum autoantibodies against heat-shock proteins in multiple sclerosis: a comparison with other inflammatory neurological disorders. J. Neurol. 2001; 248 (supplement 2):S174 (abstract)

Lily O, Vincent A, Lawrence N and Palace J. Serum autoantibodies against a neuronal cell line correlate with disability in multiple sclerosis. J. Neurol. Sci 2001;187 (supplement 1):S234 (abstract)

Lily O, Vincent A, and Palace J. Anti-neuronal antibodies in multiple sclerosis. J. Neuroimmunol. 2001;118 (supplement 1):S85 (abstract)

Vincent A, Lily O, Palace J. Pathogenic autoantibodies to neuronal proteins in neurological disorders. J Neuroimmunol. 1999;100(1-2):169-80 (review)

## **Interests**

I play bass guitar in a band that plays covers of 1960's songs. I have travelled extensively and worked on a fairground in the USA. My other interests include cycling and crossfit.

## **Referees**

Dr H Ford  
Consultant Neurologist  
The General Infirmary  
Leeds  
LS1 3AX  
Tel 0113 3928139  
Fax. 0113 3926092

Dr J Bamford  
Consultant Neurologist  
The General Infirmary  
Leeds  
LS1 3AX  
Tel. 0113 3928118  
Fax. 0113 3926092

Dr P Goulding  
Consultant Neurologist  
The General Infirmary  
Leeds  
LS1 3AX  
Tel. 0113 3922839  
Fax. 0113 3926092